Gestational diabetes & diabetes in pregnancy
The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial
- stopped early for futility
Authors' conclusion
Advancing universal GDM screening to midpregnancy at 18-20 weeks' gestation may not improve pregnancy outcomes, except for a reduction in neonatal hypoglycemia. Newborns of women diagnosed with GDM through midpregnancy screening had higher neonatal adiposity.
Study context
- Population
- Singleton pregnant women; Gestational diabetes mellitus (GDM) diagnosed by IADPSG criteriaITT analysis
- Participants
- 967 women
- Comparison
- Midpregnancy GDM screening at 18-20 weeks' gestation vs standard screening at 24-28 weeks' gestation
- Primary endpoint
- Composite of:
- Primary cesarean delivery
- Birth weight >90th percentile
- Neonatal hypoglycemia
- Cord serum C-peptide >90th percentile
- Gestational hypertension
- Preeclampsia
- Birth trauma
Methodological detailsdual-center, parallel, planned interim analysis
- Dual-center
- Parallel
- Planned interim analysis
Primary result
As reported in the abstract
Primary composite outcome
- Primary outcome not significantly different between the two groups
- Interim analysis
- Intention-to-treat
- Trial stopped early for futility
Further findings
Neonatal hypoglycemia
- Significantly lower with midpregnancy vs standard screening
Neonatal adiposity (women with GDM)
- Higher with midpregnancy vs standard screening
Safety
- Adverse event rates similar between the two groups
Original publication
The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial. Diabetes Care. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →